Slide 1: Natural Human Antibodies to Treat Human Diseases
For personal use only Natural Human Antibodies to Treat Human Diseases Dan Devine Chief Executive Officer Lodge Mid Cap Confab - 10 April 2008
Slide 2: One Company – Multiple Value Drivers
For personal use only One Company – Multiple Value Drivers Therapeutic and intellectual property advantages in one of biotech’s largest segments – antibody therapeutics Deep pipeline allows for internal development and partnering, an optimum spread of risk and reward Patrys’ lead products each
Slide 3: Review of July '07 IPO Objectives
For personal use only Review of July ‘07 IPO Objectives Evaluate two lead products in human clinical trials On schedule to produce Phase I/IIa data by Oct. 2009 Generate new products and intellectual property Added 2 new lead products 2 new disease targets discovered Advancing 15 antibod
Slide 4: Antibody Therapies: Biotech's Leading Segment
For personal use only Antibody Therapies: Biotech’s Leading Segment $14.0 Over 20 antibodies on $12.0 market $10.0 Cancer leading the $8.0 way: 4 products over US$1 billion per $6.0 annum $4.0 Significant commercial $2.0 markets (US$ billion)*: $- 2004 2005 2006 2007 2008 2009 Oncology Autoimm
Slide 5: Industry Demand for Antibody Products
For personal use only Industry Demand for Antibody Products 2004 – 2008 Avg Deal Values by Stage (US$M) 2008 Avg Deal Values Rise (US$M) $292 $225 $138 $116 $ $18 $39 $28 $25 2007 2008 Preclinical ec ca Phase ase I/II / Upfront Milestone Upfront Milestone *Based on publicly available information 5
Slide 6: Industry Demand for Antibody Companies
For personal use only Industry Demand for Antibody Companies M&A Activity continues to be strong . . . . . Purchaser Acquired Date Value US$M Stage Completed Roche Ther H HumPolyclonals mPol clonals 2007 $56 Preclinical/Technolog Preclinical/Technology Merck Abmaxis 2007 $80 Preclinical/Technology C
Slide 7: Antibody Company Values Reflect Advances
For personal use only Antibody Company Values Reflect Advances 2003 to 2008 Average Value of Antibody Company M&A Deals (US$’000) $8,600 $398 $1,545 Preclinical/Technology Phase I/Phase II Phase Ph III/Approved III/A d 7
Slide 8: Natural Human Antibody Technology
For personal use only Natural Human Antibody Technology Antibodies are produced by human “B Cells” and neutralise disease in most cases In vast majority of cases, the body makes natural human antibodies that attack and kill cancerous cells before tumours are formed Because the body produces th
Slide 9: Patrys Disease Targets – Ultimate Barrier to Entry
For personal use only Patrys Disease Targets – Ultimate Barrier to Entry “Disease target” is located on surface of cancer cell to which antibody binds and through which antibody kills the cancer cell Once Patrys identifies anti-cancer natural human antibody, it then uses antibody to identify res
Slide 10: One Platform – Diverse Products and Applications
For personal use only One Platform – Diverse Products and Applications Effective in Shown Potential Lead GMP License Product Animal Efficacy in Indications* Selection Manuf Partnering Studies Human Trial PAT - LM1 All unique Lung colon Lung, PAT - SM6 Melanoma, gastric PAT - CM1 Colon products wit
Slide 11: PAT-SC1: Pipeline Value Proof of Concept
For personal use only PAT-SC1:Pipeline Value Proof of Concept Probability of Survival 100% Treated Treated patients (35) had 90% significantly f higher survival rate 80% No significant adverse events 70% Low dose (< 10% of marketed 60% anti-cancer antibodies) 50% Untreated This survival data
Slide 12: PAT-LM1 and PAT-SM6 Lead Products
For personal use only PAT-LM1 and PAT-SM6 Lead Products Factor PAT-SC1 PAT-LM1 PAT-SM6 Efficacy established in multiple Efficacy established in multiple Positive laboratory & animal studies laboratory & animal studies POC Human Data Phase I/IIa data on target for Oct. Phase I/IIa data on target for
Slide 13: Products Target Unmet Medical Needs
For personal use only Products Target Unmet Medical Needs 5 Year Mortality Rates for Targeted Cancers (U.S. National Cancer Institute ) 100% 90% Patrys lead products 80% target many cancers 70% including lung, pancreatic gastric, pancreatic, gastric 60% colon and melanoma 50% 40% Markets for the
Slide 14: Potential Advantages of Natural Human Antibodies
For personal use only Potential Advantages of Natural Human Antibodies Antibodies on Market From Patrys Natural Human Factor Non-Human Non Human Sources Antibodies Attack healthy tissues and Ignore healthy tissues Safety organs, greater risks screened, less adverse events Compromises ability t
Slide 15: Proprietary Disease Targets – Protected Franchise
For personal use only Proprietary Disease Targets – Protected Franchise Cancer Disease Marketed Antibody/ Other Antibodies in g Target Patrys y Antibody y the Clinic CD20 Rituximab/Rituxan 10 EGFR Cetuximab (Erbitux) 12 HER2 Trastuzumab (Herceptin) 9 VEGF Bevacizumab (Avastin) 5 GRP78** PAT-SM6 0 CD
Slide 16: Product Collaborations
For personal use only Product Collaborations Takeda – Covers 5 product candidates: Includes less mature lead and back-up antibodies from pipeline Takeda testing to end CY’08, then short time to negotiate license Patrys retains all IP; no pre-agreed license terms AstraZeneca – Exclusive rig
Slide 17: Upcoming Key Milestones
For personal use only Upcoming Key Milestones PAT-SM6 and PAT-LM1 Products: GMP manufacturing f t i scale-up: l M 2008 May Large animal safety studies for IND approval: complete CY08 Initiate human trials: Q1CY09 Phase I/IIa human data: October 2009 Additional Value Drivers: Takeda and
Slide 18: Summary
For personal use only Summary Asset A t rich: i h platform, l tf products d t and d cash h Blend of internal and external development Substantial value to be realized 18